𝔖 Bobbio Scriptorium
✦   LIBER   ✦

424 RESPIRATORY ALTERATIONS IN GENOTYPE 2/3 CHRONIC HEPATITIS C PATIENTS TREATED WITH PEGYLATED INTERFERON OR ALBINTERFERON-ALFA-2B PLUS RIBAVIRIN IN A RANDOMIZED STUDY

✍ Scribed by G. Foster; R. Flisiak; W.-L. Chuang; J. George; J. Rasenack; A. Sood; P. Komolmit; S. Thongsawat; T. Tanwandee; R. Sola; W. Sukeepaisarnjaroen; M. Weltman; Y. Yin; G. Feutren; K. Brown

Book ID
117379569
Publisher
Elsevier Science
Year
2011
Tongue
English
Weight
120 KB
Volume
54
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Pegylated interferon alpha-2b plus ribav
Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: Some issues
✍ Ming-Lung Yu; Chia-Yen Dai; Jee-Fu Huang; Ming-Yen Hsieh; Wan-Long Chuang πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 63 KB πŸ‘ 2 views

accurate representation of the data is given in Table 1. 7. The major conclusion of this paper was that monitoring hepatitis C virus RNA levels and varying the duration of therapy can save resources without sacrificing rates of SVR. The authors used the Blackwelder test to test the noninferiority of

Albinterferon alfa-2b dosed every two or
Albinterferon alfa-2b dosed every two or four weeks in interferon-naΓ―ve patients with genotype 1 chronic hepatitis C
✍ Stefan Zeuzem; Eric M. Yoshida; Yves Benhamou; Stephen Pianko; Vincent G. Bain; πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 528 KB

The efficacy and safety of albinterferon alfa-2b (alb-IFN), a novel recombinant protein consisting of interferon alfa-2b genetically fused to human albumin, was evaluated in a phase 2b, open-label study of patients with genotype 1, chronic hepatitis C. In all, 458 IFN-alfa treatment-naΔ± Β¨ve patients